...
首页> 外文期刊>Cell death & disease. >MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy
【24h】

MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy

机译:MiR-26通过抑制自噬增强化学敏感性并促进肝癌细胞的凋亡

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Hepatocellular carcinoma (HCC) generally possesses a high resistance to chemotherapy. Given that autophagy is an important factor promoting tumor chemoresistance and HCC express low level of miR-26, we aim to investigate the functional role of miR-26 in autophagy-mediated chemoresistance of HCC. We found that chemotherapeutic drug doxorubicin (Dox) induced autophagy but decreased the level of miR-26a/b in HCC cells. Activating autophagy using rapamycin can directly downregulate the level of miR-26a/b in HCC cells. In turn, restoring the expression of miR-26a/b inhibited autophagy induced by Dox and promoted apoptosis in HCC cells. Further mechanistic study identified that miR-26a and miR-26b target ULK1, a critical initiator of autophagy, at post-transcriptional level. Results from 30 cases of patients with HCC also showed that tumor cellular levels of miR-26a and miR-26b are significantly downregulated as compared with the corresponding control tissues and negatively correlated with the protein level of ULK1 but are not correlated to the mRNA level of ULK1. Gain- and loss-of-function assay confirmed that miR-26a/b inhibited autophagic flux at the initial stage through targeting ULK1. Overexpression of miR-26a/b enhanced the sensitivity of HCC cells to Dox and promoted apoptosis via inhibiting autophagy in vitro . Using xenograft models in nude mice, we confirmed that miR-26a/b, via inhibiting autophagy, promoted apoptosis and sensitized hepatomas to Dox treatment in vivo . Our findings demonstrate for the first time that miR-26a/b can promote apoptosis and sensitize HCC to chemotherapy via suppressing the expression of autophagy initiator ULK1, and provide the reduction of miR-26a/b in HCC as a novel mechanism of tumor chemoresistance.
机译:肝细胞癌(HCC)通常对化疗具有很高的抵抗力。鉴于自噬是促进肿瘤化学耐药性的重要因素,并且HCC表达低水平的miR-26,我们旨在研究miR-26在自噬介导的HCC化学耐药中的功能。我们发现化疗药物阿霉素(Dox)诱导自噬,但降低了HCC细胞中miR-26a / b的水平。使用雷帕霉素激活自噬可以直接下调HCC细胞中miR-26a / b的水平。反过来,恢复miR-26a / b的表达可抑制Dox诱导的自噬并促进HCC细胞凋亡。进一步的机理研究确定,miR-26a和miR-26b在转录后水平上靶向ULK1,ULK1是自噬的关键启动子。 30例HCC患者的结果还显示,与相应的对照组织相比,miR-26a和miR-26b的肿瘤细胞水平显着下调,与ULK1的蛋白质水平呈负相关,但与mRNA的mRNA水平无关。 ULK1。功能获得和功能丧失测定证实,miR-26a / b通过靶向ULK1在初始阶段抑制自噬通量。 miR-26a / b的过表达增强了HCC细胞对Dox的敏感性,并通过抑制自噬作用促进了细胞凋亡。在裸鼠中使用异种移植模型,我们证实了miR-26a / b通过抑制自噬作用,促进了细胞凋亡,并使体内的肝癌对Dox治疗产生了体内敏感性。我们的发现首次证明,miR-26a / b可以通过抑制自噬引发剂ULK1的表达来促进细胞凋亡并使HCC对化学疗法敏感,并提供miR-26a / b在HCC中的降低,这是一种新型的肿瘤化学耐药机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号